Neuroendocrine Tumor Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Pfizer, Hutchison Medipharma, Ipsen, Provectus

Neuroendocrine Tumor Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Pfizer, Hutchison Medipharma, Ipsen, Provectus
DelveInsight’s “Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroendocrine Tumor.

DelveInsight’s “Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroendocrine Tumor Market Forecast

 

Some of the key facts of the Neuroendocrine Tumor Market Report: 

  • The Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • NETs develop most commonly in the GI tract, specifically in the large intestine (20%), small intestine (19%), and appendix (4%)
  • In the same study, an estimated 8,088 patients were seen to receive treatment for GI-NETs. The prevalence was estimated to be 6.42/100,000, with an annual onset incidence of 3.51/100,000. The locations of GINETs varied: foregut, 26.1%; midgut, 3.6%; and hindgut, 70.3%
  • Key Neuroendocrine Tumor Companies: Pfizer, Hutchison Medipharma, Ipsen, Provectus Biopharma, ITM Isotopen Technologien Muenche, Camurus AB, Hutchison Medipharma Ltd, Radiomedix, Inc., Novartis, Ascentage Pharma, Radiomedix, Inc., and others
  • Key Neuroendocrine Tumor Therapies: Sunitinib, Surufatinib, Lanreotide, Rose bengal, 177Lu-edotreotide PRRT, CAM2029, Surufatinib, AlphaMedix, octreotide, Pelcitoclax, 64Cu-DOTATATE, and others
  • The Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroendocrine Tumor pipeline products will significantly revolutionize the Neuroendocrine Tumor market dynamics.

 

Neuroendocrine Tumor Overview

According to the Neuroendocrine Tumor Patient Foundation (n.d.)- “Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells.

 

Get a Free sample for the Neuroendocrine Tumor Market Report 

https://www.delveinsight.com/sample-request/neuroendocrine-tumors-market

 

Neuroendocrine Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Neuroendocrine Tumor Epidemiology Segmentation:

The Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Neuroendocrine Tumor
  • Prevalent Cases of Neuroendocrine Tumor by severity
  • Gender-specific Prevalence of Neuroendocrine Tumor
  • Diagnosed Cases of Episodic and Chronic Neuroendocrine Tumor

 

Download the report to understand which factors are driving Neuroendocrine Tumor epidemiology trends @ Neuroendocrine Tumor Epidemiology Forecast

 

Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Neuroendocrine Tumor Therapies and Key Companies

  • Sunitinib: Pfizer
  • Surufatinib: Hutchison Medipharma
  • Lanreotide: Ipsen
  • Rose bengal: Provectus Biopharma
  • 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenche
  • CAM2029: Camurus AB
  • Surufatinib: Hutchison Medipharma Limited
  • AlphaMedix: Radiomedix, Inc.
  • octreotide: Novartis
  • Pelcitoclax: Ascentage Pharma
  • 64Cu-DOTATATE: Radiomedix, Inc.

 

Discover more about therapies set to grab major Neuroendocrine Tumor market share @ Neuroendocrine Tumor Treatment Market

 

Scope of the Neuroendocrine Tumor Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Neuroendocrine Tumor Companies: Pfizer, Hutchison Medipharma, Ipsen, Provectus Biopharma, ITM Isotopen Technologien Muenche, Camurus AB, Hutchison Medipharma Ltd, Radiomedix, Inc., Novartis, Ascentage Pharma, Radiomedix, Inc., and others
  • Key Neuroendocrine Tumor Therapies: Sunitinib, Surufatinib, Lanreotide, Rose bengal, 177Lu-edotreotide PRRT, CAM2029, Surufatinib, AlphaMedix, octreotide, Pelcitoclax, 64Cu-DOTATATE, and others
  • Neuroendocrine Tumor Therapeutic Assessment: Neuroendocrine Tumor current marketed and Neuroendocrine Tumor emerging therapies
  • Neuroendocrine Tumor Market Dynamics: Neuroendocrine Tumor market drivers and Neuroendocrine Tumor market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumor Market Access and Reimbursement 

 

To know more about Neuroendocrine Tumor companies working in the treatment market, visit @ Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Neuroendocrine Tumor

3. SWOT analysis of Neuroendocrine Tumor

4. Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Neuroendocrine Tumor Market Overview at a Glance

6. Neuroendocrine Tumor Disease Background and Overview

7. Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuroendocrine Tumor 

9. Neuroendocrine Tumor Current Treatment and Medical Practices

10. Neuroendocrine Tumor Unmet Needs

11. Neuroendocrine Tumor Emerging Therapies

12. Neuroendocrine Tumor Market Outlook

13. Country-Wise Neuroendocrine Tumor Market Analysis (2019–2032)

14. Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Neuroendocrine Tumor Market Drivers

16. Neuroendocrine Tumor Market Barriers

17.  Neuroendocrine Tumor Appendix

18. Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services


Posted

in

by

Tags: